Hepatocellular Carcinoma
Conditions
Interventions
Capecitabine, Peginterferon Alfa-2a
Sponsors
Chiba University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) 20 years-old (Gender does not matter). 2) Acquisition of written informed consent. 3) Have been diagnosed with hepatocellular carcinoma. 4) Surgical resection or local therapy is unlikely to lead to complete necrosis. 5) Not suitable for treatment with sorafenib. 6) ECOG performance status of 0-2. 7) Child-Pugh A. 8) Expected survival more than 12 weeks 9) Among patients who fulfill the inclusion criteria.
Exclusion criteria
Exclusion criteria: 1) Patients with a history of malignancy. 2) Corresponding to the sever heart disease. 3) Active clinically-serious infections. 4) History of HIV infection. 5) Hemodialysis. 6) Clinical or radiological evidence of CNS metastases. 7) Uncontrollable massive ascites, pleural effusion. 8) Clinically-significant gastrointestinal bleeding within 4 weeks prior to study entry. 9) Severe allergy for fluoropyrimidines. 10) HBV-DNA positive and not being treated with nucleotide analogues. 11) Anticoagulant therapy with warfarin potassium. 12) During treatment with Tegafur gimeracil oteracil potassium, or within 7 days after discontinuation. 13) Use Sho-saiko-to. 14) Use oral phenytoin. 15) Severe thyroid disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Progression (TTP) | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) Progression Free Survival (PFS) Response Rate (RR) Safety | — |
Countries
Japan
Contacts
Public ContactSadahisa Ogasawara
Chiba University Hospital Department of Gastroenterology
Outcome results
None listed